Preventing anthracycline-induced cardiotoxicity with ivabradine: A systematic review and meta-analysis

Figure 1 PRISMA flow diagram representing breakdown of screened and included studies. ¹Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers). ²If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools. PICO: Population, Intervention, Control and Outcomes. Citation: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372: N71. Copyright ©The Author(s) 2021. Published by BMJ Publishing Group Ltd.[33]. The article is open access (Supplementary material).

Figure 2  Risk of bias assessment for included trials.

Figure 3 Forest plot comparing ivabradine and placebo in regard to left ventricular ejection fraction. 95%CI: 95% confidence interval.

Figure 4 Forest plot comparing ivabradine and placebo. A: Change in troponin level; B: Change in NT-proBNP; C: Change in global longitudinal strength; D: Change in systolic blood pressure; E: Change in diastolic blood pressure. 95%CI: 95% confidence interval.